ACA
TNYA icon

Aptus Capital Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Aptus Capital Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.35K Hold
12,065
– – ﹤0.01% 1509
2025
Q4 		$8.58K Hold
12,065
– – ﹤0.01% 1506
2025
Q3 		$19.5K Buy
+12,065
New +$12.2K ﹤0.01% 1352

Other funds holding TNYA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aptus Capital Advisors's TNYA Position: Q1 2026 in Review

Aptus Capital Advisors held its Tenaya Therapeutics (TNYA) position steady in Q1 2026 at 12,065 shares worth $8.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1509.

Aptus Capital Advisors first reported a position in TNYA in Q3 2025 and has held it in 3 quarters since. The position peaked at $19.5K in Q3 2025. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • Aptus Capital Advisors held 12,065 shares of Tenaya Therapeutics worth $8.35K as of Q1 2026.
  • Aptus Capital Advisors left its Tenaya Therapeutics share count unchanged in Q1 2026.
  • Tenaya Therapeutics made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q1 2026, its #1509 holding.
  • Aptus Capital Advisors first reported a position in Tenaya Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Aptus Capital Advisors's Tenaya Therapeutics position peaked at $19.5K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.